Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
134
resultados
Última actualización
31/07/2025 [07:32:00]
Resultados 50 a 75 de 134
Resumen de: US2025146074A1
The invention relates to a method of determining whether a patient diagnosed with inflammatory bowel disease (will respond to 5-ASA therapy which includes the steps of: obtaining a stool sample from the patient, analyzing the sample for the presence of microbial acetyltransferase genes capable of converting 5-ASA to the clinically ineffective N-acetyl 5-ASA, if microbial acetyltransferase genes are not present in the sample, the patient will respond to 5-ASA therapy and such therapy should be administered; if microbial acetyltransferase genes are present in the sample, the patient will not respond to 5-ASA therapy and a second line therapy should be administered.
Resumen de: US2025144219A1
The present invention provides methods for facilitating cleansing of the gastrointestinal tract of a patient prior to a diagnostic, surgical or therapeutic procedure. The methods can improve patient compliance, and thus, efficacy of the preparation. Specifically, the present methods make the gastrointestinal tract preparation composition palatable for the patient to consume. For example, for a patient preparing to undergo colonoscopy, the present methods make the bowel preparation solution taste significantly less salty.
Resumen de: CN119932179A
The invention provides a marker composition for evaluating the inflammatory enteritis treatment effect of mesenchymal stem cells and application of the marker composition, and relates to the technical field of biology. The marker composition is prepared from a Syt8 gene, a Gabrg2 gene, an Fpr1 gene and an Hs3st4 gene. The marker composition is applied to preparation of products for evaluating the treatment effect of inflammatory enteritis of subjects treated by mesenchymal stem cells, and the problem that in the prior art, a method for evaluating the treatment effect of IBD treated by the mesenchymal stem cells is lacked is solved.
Resumen de: WO2025089672A1
The present invention relates to inflammatory bowel disease model production using patient-derived intestinal organoids, and use thereof, wherein the inflammatory bowel disease model produced by an optimized production method for inflammatory bowel disease model production can be used as a patient-customized bowel disease model by constructing an evaluation method for inflammatory bowel disease drugs.
Resumen de: WO2025089672A1
The present invention relates to inflammatory bowel disease model production using patient-derived intestinal organoids, and use thereof, wherein the inflammatory bowel disease model produced by an optimized production method for inflammatory bowel disease model production can be used as a patient-customized bowel disease model by constructing an evaluation method for inflammatory bowel disease drugs.
Resumen de: WO2025089884A1
The present specification provides a method for providing information on ulcerative colitis by means of a processor, the method comprising: a step for receiving a Korean Ulcerative Colitis-Specific Questionnaire (K-UCSQ) score for an individual; and a step for determining an inflammatory bowel disease prognosis for the individual on the basis of the received K-UCSQ score.
Resumen de: CN119896715A
The invention belongs to the technical field of traditional Chinese medicines, and discloses a traditional Chinese medicine composition for treating ulcerative colitis, which is characterized in that the traditional Chinese medicine composition is prepared by extracting the following raw medicinal materials in parts by weight: 5-15 parts of ginseng, 8-25 parts of cassia twig, 5-15 parts of nutmeg, 8-25 parts of poria cocos, 8-25 parts of roasted rhizoma atractylodis macrocephalae, 5-15 parts of rhizoma zingiberis, 10-30 parts of roasted semen coicis, 1-5 parts of indigo naturalis and 2-6 parts of coptis chinensis. According to the traditional Chinese medicine composition, ginseng, rhizoma atractylodis macrocephalae and poria cocos are used as monarch drugs together, and rhizoma atractylodis macrocephalae and poria cocos have the effects of replenishing qi to invigorate the spleen and eliminating dampness and excreting dampness together; semen coicis and rhizoma zingiberis are used as ministerial drugs and co-help the monarch drugs to resolve dampness and stop diarrhea; the traditional Chinese medicine composition has the functions of invigorating the spleen, replenishing qi, warming the kidney, stopping diarrhea, excreting dampness and removing toxicity, is mainly used for treating ulcerative colitis and irritable bowel syndrome (diarrhea type) clinically, can also be used for diagnosing'diarrhea 'and'stomachache' in traditional Chinese medicine, and can be used for treating
Resumen de: WO2025085928A1
This disclosure relates generally to methods for treating an inflammatory bowel disease ("IBD", e.g., Crohn's disease or ulcerative colitis) in a patient. More particularly, this disclosure relates to methods for selecting a therapy for treating a patient suffering from an IBD. In embodiments, the foregoing can also be used to assess the severity of the IBD. The predictive aspects of said methods can facilitate and expedite the identification and stratification of IBD patient populations that are responsive to treatment with a RIPK2 inhibitor. The foregoing methods can further include treating the IBD by administering a RIPK2 inhibitor to the patient.
Resumen de: WO2025085674A1
In one aspect, the present disclosure provides a method for selecting a subject having ulcerative colitis for treatment with ADS051, or a pharmaceutically acceptable salt thereof, the method comprising: (a) measuring MRP2 seRNA in a stool sample obtained from the subject; and (b) selecting the subject for treatment when the level of MRP2 seRNA in the stool sample exceeds a threshold value. In some embodiments, the subject has moderate or severe ulcerative colitis.
Resumen de: US2025129422A1
The invention relates to methods of monitoring treatment response, disease resolution, and disease progression in subjects having inflammatory bowel disease (IBD).
Resumen de: JP2025066445A
To provide a therapeutic drug for inflammatory diseases, particularly inflammatory bowel disease, that has no serious side effects such as immunosuppression.SOLUTION: From an analysis of the mechanism of action of sulfasalazine, it has been revealed that an anti-inflammatory action occurs by increasing intracellular glutamate. An xCT inhibitor or a glutamine synthetase inhibitor that increases intracellular glutamate has been found to be effective in the treatment of inflammatory bowel disease. Furthermore, it is considered that a compound that suppresses the expression of xCT or a glutamine synthesis-inhibiting enzyme also has a therapeutic effect.SELECTED DRAWING: Figure 5D
Resumen de: EP4541373A1
The present invention provides a therapeutic agent for sepsis and/or septic shock, comprising, as an active ingredient, a compound capable of suppressing phosphorylation of threonine at position 749 in human STAT1; a method for screening for a candidate compound serving as an active ingredient of a therapeutic agent for sepsis and/or septic shock, the method comprising selecting a compound capable of suppressing phosphorylation of threonine at position 749 in human STAT1; a therapeutic agent for colitis, comprising, as an active ingredient, a compound capable of promoting phosphorylation of threonine at position 749 in human STAT1; a method for screening for a candidate compound serving as an active ingredient of a therapeutic agent for colitis, the method comprising selecting a compound capable of promoting phosphorylation of threonine at position 749 in human STAT1; a therapeutic agent for systemic lupus erythematosus, comprising, as an active ingredient, a compound capable of inhibiting human STAT1; and a method for screening for a candidate compound serving as an active ingredient of a therapeutic agent for systemic lupus erythematosus, the method comprising selecting a compound capable of inhibiting human STAT1.
Resumen de: CN119857143A
The invention provides application of CD84 as a therapeutic target in preparation of drugs for preventing and treating inflammatory bowel diseases, and belongs to the technical field of biological medicines. The CD84 is applied to development, screening or preparation of drugs for preventing and/or treating inflammatory bowel diseases as a therapeutic target. According to the application, a dextran sodium sulfate (DSS)-induced inflammatory bowel disease classical animal model is taken as an experimental subject, and the anti-CD84 antibody is taken as a drug to block the biological function of CD84, so that the degree of DSS-induced mouse enteritis can be effectively relieved, the colorectal length can be recovered, and the secretion level of inflammatory factors can be reduced. Therefore, a new strategy is provided for targeted therapy of the inflammatory bowel disease by taking the CD84 as a therapeutic target.
Resumen de: CN119856706A
The invention provides a method for constructing a mouse model for selectively knocking out integrin alpha5 molecules in fibroblasts. The method comprises the following steps: hybridizing an integrin alpha5 knockout mouse (alpha5Flox/Flox) and a Col1a2-CreERT fibroblast tool mouse; the method comprises the following steps: constructing primers, respectively performing genotype identification on F2 generations of hybrid mice, screening simultaneously positive mice, and naming the mice as alpha5Flox/Flox; after the Col1a2-CreERT mouse is grown up, tamoxifen is continuously injected into the abdominal cavity of the Col1a2-CreERT mouse for 5 days to induce expression of Cre recombinase, and the alpha5-CKO mouse of which the integrin alpha5 molecule in the fibroblast is selectively knocked out is obtained. The invention also provides an application of the alpha5-CKO mouse, and the alpha5-CKO mouse is used for constructing an IBD (Inflammation Bowel Disease) mouse model. The mouse model construction method can be used for IBD progress research by applying the mouse model with the fibroblasts selectively knocking out the integrin alpha5 molecules, and an animal model basis is provided for research on the effect and mechanism of the integrin alpha5 molecules in IBD intestinal fibrosis progress.
Resumen de: CN119837859A
The invention discloses an application of glabridin in preparation of related drugs for inhibiting epithelial-mesenchymal transition in inflammatory bowel diseases. In the epithelial-mesenchymal transformation process, epithelial cells lose cell polarity and intercellular connection, are transformed into mesenchymal cells in function and morphology, directly participate in fibroblast activation and extracellular matrix deposition and cause intestinal fibrosis, and are one of anti-fibrosis targets. According to the application of the glabrione in preparation of the medicine related to inhibition of epithelial-mesenchymal transition in the inflammatory bowel disease, provided by the invention, the expression change of epithelial cell markers Claudin-1 and E-cadherin caused by TGF-beta 1 and interstitial cell markers Vimentin, N-cadherin, Snail and alpha-SMA can be relieved, cell migration caused by TGF-beta is improved, and the epithelial-mesenchymal transition induced by TGF-beta 1 is inhibited. The research on the mechanism of action shows that by blocking a TGF-beta1/Smad2/3 signal channel and inhibiting AKT1 activation and inhibition of epithelial-mesenchymal transition, the application of the compound in inhibition of epithelial-mesenchymal transition and prevention of intestinal disease related fibrosis is prompted.
Resumen de: CN119842979A
The invention relates to the technical field of biological nucleic acid detection, in particular to a primer combination, a detection method and a kit for detecting virulent strains and variants of infectious bursal disease viruses. The primer probe combination comprises three pairs of specific primer probes designed according to VP2 gene segments of a virulent strain, a variant 1 and a variant 2 of the infectious bursal disease virus, and the sequences of the three pairs of primers are as shown in SEQ ID NO: 1-9. The primer probe combination provided by the invention can achieve the purpose of distinguishing and detecting different strains of IBDV through fluorescent quantitative RT-PCR (Reverse Transcription-Polymerase Chain Reaction). The primer probe combination provided by the invention has the advantages of high sensitivity, strong specificity and the like, and provides a new effective detection means for rapid differential diagnosis of IBDV, epidemiological investigation and prevention and control of IBD clinically.
Resumen de: CN119846227A
The invention discloses a method, a system and equipment for evaluating the treatment effect of a CCDC71L inhibitor on radiation enteritis. It is found for the first time that knock-down of CCDC71L in human colorectal epithelial cells subjected to irradiation treatment can play a role in treating radioactive injury by regulating and controlling a lipid metabolism pathway and a ferroptosis pathway. On the basis, the invention provides a method, a system and equipment for evaluating the treatment effect of the CCDC71L inhibitor on the radiation enteritis for the field, so that a doctor is assisted in evaluating the treatment effect of a patient suffering from the radiation enteritis, and a clinician is guided to formulate an individualized treatment scheme for the patient.
Resumen de: US2025122569A1
The invention relates to methods of predicting a patient's responsiveness to treatment (e.g., vedolizumab treatment) for inflammatory bowel disease (IBD).
Resumen de: WO2025079348A1
It has been revealed that, from an analysis of the mechanism regarding the action of sulfasalazine which is a therapeutic drug for inflammatory bowel disease, an anti-inflammatory action occurs by increasing intracellular glutamate. As a result of a detailed analysis, it has been revealed that a glutamine synthetase inhibitor or an xCT inhibitor which increases intracellular glutamate has a therapeutic effect on inflammatory bowel disease. Further, it is considered that a compound that suppresses expression of a glutamine synthesis inhibiting enzyme or xCT also has a therapeutic effect. An xCT inhibitor or a glutamine synthetase inhibitor is useful as a prophylactic/therapeutic drug that is for inflammatory diseases, particularly inflammatory bowel disease, and that has no serious side effects such as immunosuppression.
Resumen de: EP4537847A2
Described are oxysterols, pharmaceutical compositions including the oxysterols, and methods of using the oxysterols and compositions for treating diseases and/or disorders related to inflammation, such as necrotizing enterocolitis, mesenteric ischemia, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, lymphocytic colitis, Celiac disease, Behcet's disease, rheumatoid arthritis, psoriasis, and autoimmune thyroid disease.
Resumen de: CN119818682A
The invention belongs to PDIA1, and particularly relates to application of PDIA1 as a drug screening target in preparation of drugs for treating ulcerative colitis. The technical problem to be solved by the invention is to provide a new molecular target for recovery of intestinal epithelial barriers in ulcerative colitis. The expression level of PDIA1 in epithelial cells of patients with ulcerative colitis is higher than that of healthy people, and symptoms of ulcerative colitis can be effectively improved by inhibiting PDIA1. The invention provides a new thought for further researching the intestinal epithelial barrier recovery mechanism and the medical application of the PDIA1.
Resumen de: WO2025076081A1
The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1 A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.
Resumen de: WO2025076414A1
The disclosure provides methods for predicting response in a subject having IBD to anti-IL12 and/or anti-IL23-based therapies, and selecting an effective therapy.
Resumen de: WO2025075714A1
Described herein is a method of diagnosing and/or treating irritable bowel syndrome (IBS) in a subject. The method comprises determining a fatty acid profile in a stool sample of the subject; and comparing the fatty acid profile with a first reference profile indicating an absence of IBS or a second reference profile indicating IBS. Also described herein is a composition for treating IBS, which comprises two or more of a Monoglobaceae bacterium, a Lachnospiraceae bacterium; and a Ruminococcaceae bacterium, as well as a method of treating IBS using the same.
Nº publicación: US2025114413A1 10/04/2025
Solicitante:
MEDISYN BIO INC [US]
MEDISYN-BIO INC
Resumen de: US2025114413A1
The present disclosure relates to a formulation for supporting the growth or maintenance of bacteria in the gastrointestinal tract of an animal. Provided is the use of at least one human milk oligosaccharide in combination with pre-biotics and probiotic strains of bacteria for the manufacture of a food composition, pharmaceutical composition, food or dietary supplement, for the selective stimulation of beneficial bacteria in the gastrointestinal tract in context of a disease condition. Also provided is a synbiotic formulation comprising living beneficial bacteria formulated with at least one human milk oligosaccharide in combination with pre-biotics. In particular, synbiotic formulation is used for improving clinical biomarkers in diseases especially Crohn's disease.
BOPI
Sede Electrónica
